Clinical observation of repaglinide or glimepiride combined with glargine in the treatment of type 2 diabetic patients
- VernacularTitle:瑞格列奈或格列美脲联合甘精胰岛素治疗2型糖尿病的观察
- Author:
Xiangjin XU
;
Yiyang LIN
;
Chunmei LI
;
Shengli ZHANG
;
Yinong LI
;
Xiugao FENG
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus;
Repaglinide;
Glimepiride;
Glargine
- From:
Chinese Journal of Endocrinology and Metabolism
2008;24(2):147-148
- CountryChina
- Language:Chinese
-
Abstract:
The effects of repaglinide combined with glargine (n=31)on glucose metabolism and β-cell function were observed in the patients with type 2 diabetes after secondary sulfonylureas failure and the results were compared with glimepiride combined with glargine (n=32). The preprandial capillary blood glucose, postprandial capillary blood glucose and HbA1C in both groups after 6-month treatment were significantly reduced as compared with those at baseline (all P<0.01). The treatment with repaglinide(2 mg tid) plus glargine was more efficient than glimepiride(4 mg qd) plus glargine in improving β-cell function, ameliorating HbA1C and postprandial blood glucose excursions in patients with type 2 diabetes.